doi:10.3969/j.issn.1673-8640.2016.08.021

Abstract

CLC Number:

R446.1

Figures/Tables 1

References 11

[1]	周建松. 血清同型半胱氨酸及超敏C反应蛋白检测在冠心病中的临床价值[J]. 中国临床研究,2011,24(4):324-325.
[2]	刘力生,王文,姚崇华. 中国高血压防治指南(2009年基层版)[J]. 中华高血压杂志,2010,18(1):11-30.
[3]	董怀平,李庆敏,张延强. 胱抑素C、血清肌酐和内生肌酐清除率在糖尿病肾病早期诊断中的效能比较[J]. 国际检验医学杂志,2008,29(2):177-178.
[4]	卞炳贤,周韵斓,沈立松. 肾小球滤过率评估方程在不同人群中的适用性[J]. 检验医学,2015,30(7):680-683.
[5]	王依屹,张珏,鲁传翠,等. 血清NGAL、Cys C和尿NAG联合检测在糖尿病肾病诊断中的临床意义[J]. 检验医学,2015,30(11):1096-1099.
[6]	王炜. 尿mAlb及血清Cys C、β2-MG联合检测在糖尿病早期肾损伤诊断中的临床应用[J]. 检验医学,2010,25(12):933.
[7]	杜松柏. 高血压病与高尿酸血症的相关性探讨[J]. 实用心脑肺血管病杂志,2012,20(3):501-502.
[8]	方玉才,曾瑞梅,蒋洪平,等. 2型DMAP患者血清CysC、RBP、β2-MG联合检测的临床意义[J]. 检验医学,2011,26(3):200-201.
[9]	珠勒皮亚·司马义,陈玉岚,布海力且木·买买提. 原发性高血压老年患者C-反应蛋白、同型半胱氨酸水平变化与颈动脉粥样硬化、左室肥厚关系[J]. 中国临床保健杂志,2013,16(1):1-3.
[10]	王国戗,杨彩玲,郭丽娟. 不同血压水平人群血管危险因子检测及其临床意义探讨[J]. 检验医学,2014,29(3):254-257.
[11]	施新明,陆怡德,毛客自,等. 高敏C反应蛋白与载脂蛋白A-1、甘油三酯联合检测在心血管疾病中的应用[J]. 检验医学,2014,29(6):690-691.

组别	例数	Cys C（mg/L）	UA（μmol/L）	β₂-MG（mg/L）	CRP（mg/L）
高血压组	380	2.41±0.35^*	425.3±92.5^*	3.07±0.91^*	10.35±1.57^*
正常对照组	50	0.75±0.25	315.7±45.9	1.15±0.46	1.58±1.32

组别	例数	Cys C（mg/L）	UA（μmol/L）	β₂-MG（mg/L）	CRP（mg/L）
高血压组	380	2.41±0.35^*	425.3±92.5^*	3.07±0.91^*	10.35±1.57^*
正常对照组	50	0.75±0.25	315.7±45.9	1.15±0.46	1.58±1.32

[1]	FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114.
[2]	SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120.
[3]	LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129.
[4]	YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140.
[5]	XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146.
[6]	CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152.
[7]	. [J]. Laboratory Medicine, 2023, 38(12): 1153-1156.
[8]	. [J]. Laboratory Medicine, 2023, 38(12): 1157-1159.
[9]	WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166.
[10]	YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172.
[11]	DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176.
[12]	GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182.
[13]	. [J]. Laboratory Medicine, 2023, 38(12): 1183-1185.
[14]	. [J]. Laboratory Medicine, 2023, 38(12): 1186-1190.
[15]	. [J]. Laboratory Medicine, 2023, 38(12): 1191-1194.

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 1

References 11

Related Articles 15

Recommended Articles

Metrics